News

The programme is focused on advanced liver cancer where current chemotherapeutic treatment options are limited and the typical survival period is six months.  Midatech is pursuing improved forms

LIQUENT InSight for IDMP is the newest module added to PAREXEL’s Regulatory Information Management (RIM) platform.  Beginning in 2018, the European Medicines Agency (EMA) will require biopharmaceutical companies to submit

PKC412 is indicated to treat AML in newly-diagnosed adults with an FMS-like tyrosine kinase-3 (FLT3) mutation, as well as for the treatment of advanced systemic mastocytosis (SM). The

Parsabiv is a calcimimetic agent where a healthcare provider can administer it intravenously three times per week at the end of a hemodialysis session. A calcimimetic is a

CPI-444 is a selective and potent inhibitor of the adenosine A2A receptor. The data were presented today in a poster session by John Powderly II, M.D., founder and

CHMP recommended the use of Suliqua in combination with metformin for the treatment of adults with type 2 diabetes mellitus to improve glycemic control when this has not been

The acquisition will mark Eagle’s entry into biologics, the fastest growing sector of the pharmaceuticals market, and will allow the Company to apply its proven market strategy to

The Prospective Randomized Evaluation of CelecoxibIntegrated Safety vs. Ibuprofen Or Naproxen (Precision) demonstrated that Celebrex has similar cardiovascular risk as compared to prescription doses Of Ibuprofen and Naproxen. The findings contradict some of the researchers’ belief

The approval allows the company to use Ibrance in combination with an aromatase inhibitor. It also allows the use of Ibrance in combination with fulvestrant to treat women who